Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | GUSB | P08236 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31673809 | 0.89 | LMNA (0.73) | NPC1GUSBMAPTLMNAKDM4E | |
| SCHEMBL15101603 | 0.89 | LMNA (0.73) | NPC1GUSBMAPTLMNAKDM4E | |
| SCHEMBL23786554 | 0.88 | L3MBTL1 (0.74) | NPC1GUSBMAPTLMNAKDM4E | |
| SCHEMBL4633311 | 0.85 | TSHR (0.67) | NPC1GUSBMAPTLMNAKDM4E | |
| SCHEMBL4816937 | 0.85 | LMNA (0.68) | NPC1GUSBMAPTLMNAKDM4E | |
| Hydrochloric Acid SCHEMBL4819171 | 0.84 | LMNA (0.71) | NPC1GUSBMAPTLMNAKDM4E | |
| SCHEMBL10000195 | 0.84 | LMNA (0.80) | NPC1GUSBMAPTLMNAKDM4E | |
| SCHEMBL25174836 | 0.83 | TGFBR1 (0.69) | NPC1GUSBMAPTLMNAKDM4E | |
| SCHEMBL1063094 | 0.83 | NPC1 (1.00) | NPC1GUSBMAPTLMNAKDM4E | |
| SCHEMBL1061819 | 0.82 | LMNA (0.65) | NPC1GUSBMAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142682-A1 | ANTIVIRULENCE COMPOUNDS INHIBITING BACTERIAL MONO-ADP-RIBOSYLTRANSFERASE TOXINS | UNIVERSITY OF GUELPH (CA) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142682-A1 | ANTIVIRULENCE COMPOUNDS INHIBITING BACTERIAL MONO-ADP-RIBOSYLTRANSFERASE TOXINS | TIPARP, CD38, PARP14 | NPC1 4728/4885GUSB 3579/4885MAPT 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.